Healthy
Conditions
Keywords
Healthy, Canagliflozin, Metformin, JNJ-28431754, GLUMETZA®, Bioequivalence, Fixed Dose Combination
Brief summary
The purpose of this study is to assess the bioequivalence (similarity of the drug amount in blood among the formulations) of the fixed dose combination (two components combined in one tablet) of canagliflozin and metformin extended release (XR) tablet (dose of 2 X 150 mg/500mg) with respect to the individual components of canagliflozin (1 x 300 mg) and metformin XR tablet (2 x 500 mg) in healthy fed participants.
Detailed description
This is a randomized (the study medication is assigned by chance), open-label (physicians and participants know the identity of the assigned treatment), single-center, single-dose, 3-treatment, 3-way crossover (the same medications provided to all participants but in different sequence) study of a Fixed Dose Combination (FDC) tablets of canagliflozin (CANA) and metformin extended release (MET XR) in comparison with tablets of individual components. Two FDC tablets will be studied with different formulations of MET XR component (CANA component will be identical). Both FDCs will be of the same strength: 2 tablets of 150mg CANA/500mg MET XR and will be compared with the equal doses of the individual drugs: canagliflozin (1 x 300mg tablet) and metformin XR (2 x 500mg tablets). Thus, there will be 3 treatment periods in the study: Treatment A: Reference treatment of individual components. Treatment B: CANA/MET XR FDC, formulation 1; and Treatment C: CANA/MET XR FDC, formulation 2. Approximately 42 healthy adult participants will be randomly assigned to 1 of 3 treatments groups, and then each group will receive all three treatments in different sequences (3-way crossover). The study will consist of 3 phases: a Screening Phase of approximately 3 weeks (Days -22 to -2), an Open-Label Treatment Phase consisting of 3 single-dose Treatment Periods of 5 days each (Days -1 through 4) separated by a washout of 10 to 14 days between Day 1 of each Treatment Period, and a Follow-up Phase occurring 7 to 10 days after the last study-related procedure on Day 4 of Treatment Period 3. The total duration of the study will be about 70 days for each participant.
Interventions
Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
DRUGCANA/MET XR FDC, Formulation 1, 150 mg/500
Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.
DRUGCANA/MET XR FDC, Formulation 2, 150 mg/500 mg
Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Must sign an informed consent document indicating they understand the purpose of the study and procedures * Must have a body mass index (BMI) of between 18 and 30 kg/m², inclusive * Must have a body weight of not less than 50 kg * Must have a blood pressure between 90 and 140 mmHg inclusive, systolic, and no higher than 90 mmHg diastolic at screening * Must have normal renal function and no evidence of kidney damage (including abnormalities in blood or urine tests)
Exclusion criteria
* History of or current clinically significant medical illness * Use of any prescription or nonprescription medication (including vitamins and herbal supplements) * History of clinically significant allergies, especially known hypersensitivity or intolerance to drugs or lactose * Known allergy to heparin or history of heparin induced thrombocytopenia * Donated blood or blood products or had substantial loss of blood within 3 months before screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma concentration of canagliflozin following the single dose of drug administration | Day 1 to Day 2 (predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours postdose); Day 3 (48 hour); and Day 4 | Plasma concentrations of canagliflozin are used to evaluate how long canagliflozin stays in the body. |
| Plasma concentration of metformin extended release following the single dose of drug administration | Day 1 to Day 2 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, and 30 hours postdose); and Day 3 (36 hours) | Plasma concentrations of metformin are used to evaluate how long it stays in the body. |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events as a measure of safety and tolerability | Up to Day 10 of the follow-up period |
Countries
United States
Outcome results
None listed